A therapeutic that simultaneously reduces the levels of both MALAT1 and MENβ could be advantageous for cancers experiencing an upregulation of MALAT1 and MENβ, such as lung, breast, colorectal and many other cancer types [9,10,79,80,81]. The gene discussed is MALAT1; the disease is cancer.